BioCryst (NASDAQ:BCRX) announced today that it is canceling its merger with Presidio Pharmaceuticals, an event that Motley Fool health care analyst Brenton Flynn predicted could happen last month. With BioCryst's Hep-C candidate impaired, and companies like Abbott (NYSE:ABT) and Gilead (NYSE:GILD) already light-years ahead in the race for an all-oral Hepatitis C regimen, it's easy to understand why a deal for Presidio and its phase-2-ready drug didn't make sense.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
